McClellan's FDA Team
This article was originally published in RPM Report
Executive Summary
When Mark McClellan became FDA commissioner in late 2002, he brought with him a cadre of like-minded managers and policy advisors. Many were economists; all were advocates for private-sector innovation. Most have departed from FDA. Their departures may have some short-term political benefits for the agency; but they leave a legacy of economic interest in the way FDA works and affects society.
You may also be interested in...
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
As DC Speculates on Democrats in 2009, Some Old FDA Hands Come Into View
No matter who wins, the 2008 Presidential election means there will be widespread personnel changes across key federal health agencies. Two ex-FDA officials look particularly ready to resurface should the Democrats take back the White House.
FDA Leadership Changes Reflect Budgetary, Scientific Challenges
FDA has a new chief operating officer and medical officer. The appointments reflect the challenges of a lean budget and calls for a chief scientist from the Institute of Medicine.